Sign in Subscribe
Drug resistance

NeuroBlate System Demonstrates Long-Term Effectiveness and Safety in Treating Drug-Resistant Epilepsy

Strategic Insights

— 2 min read

A landmark study published in JAMA Neurology has provided definitive evidence that the NeuroBlate System is a safe, durable, and minimally invasive surgical option for drug-resistant mesial temporal lobe epilepsy (MTLE). The study, conducted by Monteris Medical, drew from the company's 1,000+ patient LAANTERN research initiative and analyzed 145 patients across 15 U.S. institutions. The study's findings reveal long-term seizure freedom outcomes comparable to anterior temporal lobectomy (ATL), with 58.4% and 57.2% of patients achieving Engel 1 and International League Against Epilepsy (ILAE) 1/2 seizure freedom classifications at one and two years, respectively. The study also highlighted the benefits of the NeuroBlate procedure, including short hospitalizations, low readmission rates, and positive recovery outcomes, with nearly all patients discharged to their homes post-procedure.

Key Takeaways:

  • The NeuroBlate System has demonstrated long-term effectiveness and safety in treating drug-resistant mesial temporal lobe epilepsy (MTLE).
  • The study showed that 58.4% and 57.2% of patients achieved Engel 1 and International League Against Epilepsy (ILAE) 1/2 seizure freedom classifications at one and two years, respectively.
  • The NeuroBlate procedure resulted in short hospitalizations, low readmission rates, and positive recovery outcomes, with nearly all patients discharged to their homes post-procedure.
  • The study also highlighted the benefits of the NeuroBlate procedure, including the elimination of the need for open brain surgery and the reduction of hospitalization and recovery time.
  • The study's findings are consistent with previously published evidence that laser ablation is a viable option for pediatric epilepsy, and comparable outcomes were observed between pediatric and adult patients.
  • The study demonstrated meaningful surgical time savings when ROSA robotics were used for cranial access versus the Clearpoint Navigation System.
  • The study's outcomes, including safety, quality of life, and health economics, were evaluated over a five-year period.
  • More than one-third (34.9%) of patients either stopped or reduced their use of anti-seizure medications following the procedure.

Statistics:

  • 145 patients were enrolled in the study across 15 U.S. institutions.
  • The study analyzed data from over 1,000 patients in the LAANTERN research initiative.
  • 58.4% of patients achieved Engel 1 seizure freedom classification at one year.
  • 57.2% of patients achieved International League Against Epilepsy (ILAE) 1/2 seizure freedom classification at two years.
  • 34.9% of patients either stopped or reduced their use of anti-seizure medications following the procedure.
  • The study demonstrated a 58% reduction in hospitalization and recovery time compared to traditional surgery.
  • The study showed a 25% reduction in surgical time when ROSA robotics were used for cranial access versus the Clearpoint Navigation System.

Sources:

  • Monteris Medical press release, "Monteris Medical Announces Landmark Study Supporting LITT for Drug-Resistant Epilepsy," July 16, 2025.
  • JAMA Neurology, "Laser Ablation for Drug-Resistant Epilepsy: A Prospective Multicenter Study," 2025.
  • LAANTERN study (NCT02392078).
  • Monteris Medical website, "LAANTERN (Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System)."

Read more